読み込み中
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.
前日終値
$229.23
+$6.54 · +2.94%
日中の時刻はETです。市場データは遅延する場合があります。
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.
日中レンジ
現在 $229.23
52週レンジ
現在 $229.23
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
買い
バリュエーション
65
割安
センチメント
63
強気
リスク
29
中程度のリスク
モメンタム
61
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.
日中レンジ
現在 $229.23
52週レンジ
現在 $229.23
直近の発表実績
直近の発表実績
この株式へのエクスポージャーを報告している上場投資信託です。
T. Rowe Capital Appreciation Equity ETFTCAF1.7億1.88%91.1億 USD0.31%$43.59+0.90%
iShares Biotechnology ETFIBB1.06億1.01%108.2億 USD0.44%$206.49+3.00%
iShares Russell Mid-Cap Growth ETFIWP6300.3万0.32%200.95億 USD0.23%$143.1+1.56%
iShares Russell Mid-Cap ETFIWR4930.98万0.09%567.65億 USD0.18%$109.82+0.87%
iShares Russell 1000 Growth ETFIWF4200.89万0.03%1305.08億 USD0.18%$127.91+0.63%
Sapient Quality Select ETFSQS3244万2.28%14.24億 USD0.80%$28.5901-0.24%
Vanguard Russell 1000 Growth ETFVONG2013.05万0.04%543億 USD0.06%$131.69+0.63%
First Trust Health Care AlphaDEX FundFXH1497.28万1.34%11.13億 USD0.61%$130.15+1.37%T. Rowe Capital Appreciation Equity ETFTCAFiShares Biotechnology ETFIBBiShares Russell Mid-Cap Growth ETFIWPiShares Russell Mid-Cap ETFIWRiShares Russell 1000 Growth ETFIWFSapient Quality Select ETFSQSVanguard Russell 1000 Growth ETFVONGFirst Trust Health Care AlphaDEX FundFXHAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
